RSS订阅 加入收藏  设为首页
金沙国际华人娱乐
当前位置:首页 > 金沙国际华人娱乐

金沙国际华人娱乐:FDA approved China to create innovative anti-HIV therapy medicine plate boosted again

时间:2018/3/8 18:26:20  作者:  来源:  浏览:0  评论:0
内容摘要: US FDA Announces Listing of Trogarzo for Zhongyu New Drugs, the First Innovative Bio-drug Approved by the U.S. FDA in 2018. As the first an...

US FDA Announces Listing of Trogarzo for Zhongyu New Drugs, the First Innovative Bio-drug Approved by the U.S. FDA in 2018. As the first anti-retroviral therapy with a completely new mechanism in more than 10 years, Trogarzo has obtained breakthrough drug certification, priority review qualification, fast track qualification, and orphan drug qualification issued by the US FDA, and can treat a variety of existing therapies. Adult HIV-infected persons who are not effective.

Recently, the Food and Drug Administration Bureau, Ministry of Science issued "Guidance on strengthening and promoting the work of the Food and Drug technological innovation", comments clear, focusing on innovative drugs, rare diseases therapy medical device research and development. Trogarzo and other domestic treatment of HIV innovative drugs approved by the US FDA for a continuous, meaningful indicators, is expected to trigger the funds for the treatment of HIV stocks in the domestic concern.

The pharmaceutical industry continued to rebound this week and led the way in the secondary industry. On the one hand, the overall valuation of the pharmaceutical industry is still at a low level in recent years, and the margin of safety is sufficient. On the one hand, the overall valuation of the pharmaceutical industry is still at a low level in recent years, and the margin of safety is adequate. As of the latest, the 152 pharmaceutical companies have increased their performance. FY 2017 results achieved positive growth, with 30 of them doubling year-on-year. SWS level defense defense industry index trend: performance increase, there are 152 pharmaceutical companies to achieve positive growth in 2017 annual performance, of which 30 were doubling year on year growth.

Distribution of medical stocks performance growth:

金沙国际华人娱乐:FDA_approved_China_to_create_innovative_anti-HIV_therapy_medicine_plate_boosted_again

Donghai Securities said that in the context of global stock markets successively tumbled, the February medical sector continued its weak volatility market, and consecutive declines have made part of the underlying valuations gradually attractive. Taking into account in March 2017 to enter the annual disclosure period, and held two sessions may bring good policy side, we believe that the recent investment target selection should be performance-based, considering the margin of safety; while focusing on the growth of the subject itself, and where the industry meets National medical reform, innovative drugs, two votes system, the sameness evaluation and other industrial development trend.

Biotech Unicorn launched IPO in a green channel, and the entire pharmaceutical sector was also boosted. The medical and medical funds benefited from this. China Shipping Healthcare Theme stocks (399011) layout Hengrui Medicine , Antu Biology and other leading companies. Sino-European Medical Health Mix A (003095) focuses on another pharmaceutical giant, , Fosun Pharma, . Nearly a week the above fund returns are more than 3%, showing a good market trend.

金沙国际华人娱乐:FDA_approved_China_to_create_innovative_anti-HIV_therapy_medicine_plate_boosted_again

medicine thematic funds

the phone can buy a fund account, click here to download immediately
Fund Code fund referred near June earnings fee operation
399011 sea Healthcare theme stock 21.09% 1.50 % 0.15% purchase account to buy
0030957_89 456_72_65473_9 Central Europe Healthcare mixed A19.46% 1.50% 0.15% purchase account purchase
004851 GF healthcare stock 15.36% 1.50 % 0.15% purchase account purchase 14.39%
001717 forefront of medical ICBC stock 1.50 % 0.15% purchase account to buy 7_8 9456_116_65473_9
Source: Oriental Fortune Choice data , Galaxy Securities, as of the date: 2018-03-08

Risk Warning:

finishing this report published by the Institute of Oriental Fortune Securities based on the open market data for reference only, Oriental Wealth Securities Research Can not guarantee the data authenticity, accuracy and completeness. The contents of the report do not represent the views of the Fund every day, does not constitute investment advice, investors operate accordingly, at your own risk. Market risk, the investment need to be cautious.

Shanghai Institute of Oriental Wealth Securities Limited


上一篇:没有了
下一篇:金沙国际华人娱乐:学雷锋?关爱老人
相关评论

本类更新

本类推荐

本类排行

本站所有站内信息仅供娱乐参考,不作任何商业用途,不以营利为目的,专注分享快乐,欢迎收藏本站!
所有信息均来自:百度一下 (金沙国际华人娱乐)
豫ICP备6321478980号